Company / R&D Expense
SOLENO THERAPEUTICS INC R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$40.6M
FY2025
5-year range
$15.3M / $78.6M
FY2021-FY2025
Trend
-48.3%
vs FY2024
Sector context
#184 of 209
Health Care
What the data says
SOLENO THERAPEUTICS INC's r&d expense of $41M is lower than 88% of companies in the Health Care sector (FY2025). R&D Expense has fluctuated over the past 10 years, ranging from $2M in FY2016 to $79M in FY2024.
Based on SEC 10-K filings.
$41M in FY2025 with a 5-year CAGR of +11.9%.
Improved from $25M to $41M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +38.6%
- 5-Year CAGR
- +11.9%
- 10-Year CAGR
- -
Sector benchmark
Bottom 12% in Health CareTop 88% of 209This company $40.6M Sector average $647.6M
▼
-93.7% below sector average
Key checks
Key Insights
- 5-year CAGR of +11.9%, indicating consistent growth.
- In FY2025, r&d expense decreased 48.3% year-over-year.
- Ranks #184 out of 209 companies in the Health Care sector.
- Peak r&d expense was recorded in FY2024.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $40.6M | -48.3% |
| FY2024 | $78.6M | +211.9% |
| FY2023 | $25.2M | +65.0% |
| FY2022 | $15.3M | -28.8% |
| FY2021 | $21.5M | -7.5% |
| FY2020 | $23.2M | +42.6% |
| FY2019 | $16.3M | +126.6% |
| FY2018 | $7.2M | +133.9% |
| FY2017 | $3.1M | +36.6% |
| FY2016 | $2.2M | -50.5% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026